In Genome Biology this week: loci linked to longitudinal pediatric bone accrual, role of complement cascade gene in pancreatic cancer metastases, and more.
Sema4 will use its next-generation sequencing testing services to identify patients with solid tumors harboring NRG1 fusions for Merus' Phase I/II drug trial.
Bluestar hopes to launch a pan-cancer, DNA methylation-based liquid biopsy assay as a laboratory-developed test out of an envisioned CLIA-certified lab in San Diego.
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
Genomic and epigenomic data suggest it may be possible to target an FGFR fusion found in open chromatin in a subset of adenosquamous carcinoma of the pancreas tumors.
The funding is being provided under the NYGC's Polyethnic-1000 initiative, which was launched in 2018 to study cancer care inequities in underserved populations.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
